AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 31 - (NewsRx.com & NewsRx.net) -- Parainfluenza type 3 cold passage mutant 45 live attenuated vaccine was safe and effective in healthy children 6 to 18 months old.
"A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3) -cold passage mutant 45 (cp45) vaccine was conducted in 380 children 6 to 18 months old; 226 children (59%) were seronegative for PIV3. Of the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in the occurrence of adverse events (i.e., runny nose, cough, or temperature greater than or equal to38 degrees C) was noted during the 14 days after vaccination," scientists in the United States and Australia report.
"There was no difference between groups in the occurrence of acute otitis media or serous otitis media," said Robert B. Belshe at St. Louis University in the United States and collaborators in the United States and Australia. "Paired serum samples were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative placebo recipients; 84% of seronegative vaccine recipients developed a greater than or equal to four-fold increase in antibody titers. The ...
Source: HighBeam Research, Parainfluenza type 3 vaccine safe and effective in children.